5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Redefining the IGCCCG classification in advanced non-seminoma
    Meeting Abstract

    Gillessen, S.; Collette, L.; Daugaard, G.; de Wit, R.; Tryakin, A.; Albany, C.; Stahl, O.; Fizazi, K.; Gietema, J. A.; De Giorgi, U. F. F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Tran, B.; Kouros-Mehr, H.; Fermin, A.; Horvath, L.; Roncolato, F.; Rettig, M.; Dorff, T.; Tagawa, S. T.; Subudhi, S. K.; Antonarakis, E. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Hoimes, C. J.; Rosenberg, J. E.; Srinivas, S.; Petrylak, D. P.; Milowsky, M.; Merchan, J. R.; Bilen, M. A.; Gupta, S.; Carret, A. S.; Yuan, N.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
    Meeting Abstract

    Choueiri, T. K.; Larkin, J. M. G.; Pal, S. K.; Motzer, R. J.; Venugopal, B.; Alekseev, B. Y.; Miyake, H.; Gravis, G.; Bilen, M. A.; Chudnovsky, A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
    Meeting Abstract

    Abida, W.; Campbell, D.; Patnaik, A.; Sautois, B.; Shapiro, J.; Vogelzang, N. J.; Bryce, A. H.; McDermott, R.; Ricci, F.; Rowe, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Voss, M. H.; Azad, A. A.; Hansen, A. R.; Gray, J. E.; Welsh, S. J.; Achour, I.; Hu, H.; Lewis, L.; Walcott, F. L.; Oosting, S. F.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Meeting Abstract

    Uemura, M.; Tomita, Y.; Miyake, H.; Hatakeyama, S.; Kanayama, H. O.; Numakura, K.; Takagi, T.; Kato, T.; Eto, M.; Obara, W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses
    Meeting Abstract

    Ravaud, A.; Martini, J. F.; Ching, K.; Staehler, M.; Magheli, A.; Escudier, B.; Mu, X. J.; Valota, O.; Lin, X.; Motzer, R. J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Pal, S. K.; Bajorin, D. F.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
    Meeting Abstract

    McGregor, B. A.; O'Donnell, P. H.; Balar, A.; Petrylak, D. P.; Rosenberg, J. E.; Yu, E.; Quinn, D. I.; Shah, S. N.; Pinelli, J.; Hepp, Z.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save